Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

397 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy.
Van Vaerenbergh K, Van Laethem K, Van Wijngaerden E, Schmit JC, Schneider F, Ruiz L, Clotet B, Verhofstede C, Van Wanzeele F, Muyldermans G, Simons P, Stuyver L, Hermans P, Evans C, De Clercq E, Desmyter J, Vandamme AM. Van Vaerenbergh K, et al. Among authors: vandamme am. AIDS Res Hum Retroviruses. 2000 Apr 10;16(6):529-37. doi: 10.1089/088922200308945. AIDS Res Hum Retroviruses. 2000. PMID: 10777143
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.
Van Laethem K, Schmit JC, Pelemans H, Balzarini J, Witvrouw M, Pérez-Pérez MJ, Camarasa MJ, Esnouf RM, Aquaro S, Cenci A, Perno CF, Hermans P, Sprecher S, Ruiz L, Clotet B, Van Wijngaerden E, Van Ranst M, Desmyter J, De Clercq E, Vandamme AM. Van Laethem K, et al. Among authors: vandamme am. AIDS Res Hum Retroviruses. 2000 Jun 10;16(9):825-33. doi: 10.1089/08892220050042765. AIDS Res Hum Retroviruses. 2000. PMID: 10875608
Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients.
Theys K, Deforche K, Vercauteren J, Libin P, van de Vijver DA, Albert J, Asjö B, Balotta C, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Grossman Z, Hamouda O, Horban A, Korn K, Kostrikis LG, Kücherer C, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stockl E, Riva C, Ruiz L, Liitsola K, Schmit JC, Schuurman R, Sönnerborg A, Stanekova D, Stanojevic M, Struck D, Van Laethem K, Wensing AM, Boucher CA, Vandamme AM; SPREAD-programme. Theys K, et al. Among authors: vandamme am. Retrovirology. 2012 Oct 3;9:81. doi: 10.1186/1742-4690-9-81. Retrovirology. 2012. PMID: 23031662 Free PMC article.
Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients.
Van Vaerenbergh K, Harrer T, Schmit JC, Carbonez A, Fontaine E, Kurowski M, Grünke M, Löw P, Rascu A, Schmidt B, Schmitt M, Thoelen I, Walter H, Van Laethem K, Van Ranst M, Desmyter J, De Clercq E, Vandamme AM. Van Vaerenbergh K, et al. Among authors: vandamme am. AIDS Res Hum Retroviruses. 2002 Apr 10;18(6):419-26. doi: 10.1089/088922202753614182. AIDS Res Hum Retroviruses. 2002. PMID: 11958685
397 results